JP2013515049A5 - - Google Patents

Download PDF

Info

Publication number
JP2013515049A5
JP2013515049A5 JP2012545493A JP2012545493A JP2013515049A5 JP 2013515049 A5 JP2013515049 A5 JP 2013515049A5 JP 2012545493 A JP2012545493 A JP 2012545493A JP 2012545493 A JP2012545493 A JP 2012545493A JP 2013515049 A5 JP2013515049 A5 JP 2013515049A5
Authority
JP
Japan
Prior art keywords
composition
klh
concentration
present
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012545493A
Other languages
English (en)
Japanese (ja)
Other versions
JP6007105B2 (ja
JP2013515049A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2010/055674 external-priority patent/WO2011077309A2/en
Publication of JP2013515049A publication Critical patent/JP2013515049A/ja
Publication of JP2013515049A5 publication Critical patent/JP2013515049A5/ja
Application granted granted Critical
Publication of JP6007105B2 publication Critical patent/JP6007105B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012545493A 2009-12-22 2010-12-08 ワクチン組成物 Expired - Fee Related JP6007105B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28908309P 2009-12-22 2009-12-22
US61/289,083 2009-12-22
PCT/IB2010/055674 WO2011077309A2 (en) 2009-12-22 2010-12-08 Vaccine compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015105966A Division JP6146927B2 (ja) 2009-12-22 2015-05-26 ワクチン組成物

Publications (3)

Publication Number Publication Date
JP2013515049A JP2013515049A (ja) 2013-05-02
JP2013515049A5 true JP2013515049A5 (https=) 2014-01-30
JP6007105B2 JP6007105B2 (ja) 2016-10-12

Family

ID=43797591

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012545493A Expired - Fee Related JP6007105B2 (ja) 2009-12-22 2010-12-08 ワクチン組成物
JP2015105966A Expired - Fee Related JP6146927B2 (ja) 2009-12-22 2015-05-26 ワクチン組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015105966A Expired - Fee Related JP6146927B2 (ja) 2009-12-22 2015-05-26 ワクチン組成物

Country Status (13)

Country Link
US (3) US20130034573A1 (https=)
EP (2) EP2515934B1 (https=)
JP (2) JP6007105B2 (https=)
KR (1) KR20120120185A (https=)
CN (2) CN102762224A (https=)
AU (1) AU2010334428B2 (https=)
CA (1) CA2785585A1 (https=)
IL (1) IL220308A0 (https=)
MX (1) MX337070B (https=)
NZ (2) NZ629256A (https=)
RU (1) RU2581020C2 (https=)
SG (2) SG181628A1 (https=)
WO (1) WO2011077309A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2536399T (pt) * 2010-02-21 2020-02-06 Bayer Healthcare Llc Método para ativação e conjugação de biomoléculas
KR101502360B1 (ko) * 2013-03-20 2015-03-25 주식회사 옵티팜 신규한 국내형 돼지생식기호흡기증후군 바이러스
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
KR20210027493A (ko) * 2018-07-19 2021-03-10 주식회사 헬릭스미스 네이키드 dna 유전자 요법을 위한 동결 건조된 약제학적 조성물
US20220273755A1 (en) * 2019-11-21 2022-09-01 Multiple Fortune Holding Limited Pharmaceutical composition, use and method for applying ganoderma microsporum immunomodulatory protein and keyhole limpet hemocyanin in carcinoma treatment

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH600453A5 (https=) 1976-12-30 1978-06-15 Autelca Ag
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
EP0491007B1 (en) * 1989-09-08 1996-03-13 The Johns Hopkins University Structural alterations of the egf receptor gene in human gliomas
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
US5776468A (en) 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
FR2719479B1 (fr) * 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.
EP1167379A3 (en) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
WO1996016988A1 (en) * 1994-11-28 1996-06-06 Thomas Jefferson University Reagents and processes for targeting mutant epidermal growth factor receptors
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
ATE292980T1 (de) 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
DK1005368T3 (da) 1997-03-10 2010-01-04 Ottawa Hospital Res Inst Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
EP1003850B1 (en) 1997-06-06 2009-05-27 The Regents of the University of California Inhibitors of dna immunostimulatory sequence activity
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
ES2214722T3 (es) * 1997-07-31 2004-09-16 Metra Biosystems, Inc. Metodo de ensayo de peptidos de colageno.
ATE421527T1 (de) * 1997-08-27 2009-02-15 Novartis Vaccines & Diagnostic Molekular-mimetika von meningokokkus b epitopen
AU1145699A (en) 1997-09-05 1999-03-22 Smithkline Beecham Biologicals (Sa) Oil in water emulsions containing saponins
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
WO1999052549A1 (en) 1998-04-09 1999-10-21 Smithkline Beecham Biologicals S.A. Adjuvant compositions
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
TW570805B (en) * 1998-09-01 2004-01-11 Hoffmann La Roche Water-soluble pharmaceutical composition in an ionic complex
KR100629028B1 (ko) 1998-10-16 2006-09-26 글락소스미스클라인 바이오로지칼즈 에스.에이. 애쥬번트 시스템 및 백신
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
ES2572834T3 (es) 1999-02-17 2016-06-02 Csl Limited Complejos inmunogénicos y métodos relacionados con los mismos
ATE459373T1 (de) 1999-03-19 2010-03-15 Glaxosmithkline Biolog Sa Impfstoff gegen kapsulare polysaccharide von streptococcus pneumoniae
JP2001163801A (ja) * 1999-04-02 2001-06-19 Oriental Yeast Co Ltd 乾燥ｃ反応性タンパク質組成物
PT1187629E (pt) 1999-04-19 2005-02-28 Glaxosmithkline Biolog Sa Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
HUP0202885A3 (en) 1999-09-24 2004-07-28 Smithkline Beecham Biolog Vaccines
TR200200777T2 (tr) 1999-09-24 2002-09-23 Smithkline Beecham Biologicals S.A. Polioksietilen alkil eteri veya esteriyle en az bir iyonik olmayan yüzey aktif maddeli adjuvant.
US6911204B2 (en) * 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
CN101721362B (zh) * 2002-02-14 2018-07-03 中外制药株式会社 包含抗体的溶液制剂
JP4393382B2 (ja) * 2002-08-14 2010-01-06 三菱化学株式会社 中枢性タウ蛋白質特異的抗体
JP4504098B2 (ja) * 2003-05-28 2010-07-14 武田薬品工業株式会社 抗体およびその用途
KR20130065723A (ko) * 2003-06-27 2013-06-19 암젠 프레몬트 인코포레이티드 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그 용도
ATE530165T1 (de) * 2003-11-14 2011-11-15 Baxter Int Alpha1-antitrypsin-zusammensetzungen und behandlungsverfahren unter verwendung dieser zusammensetzungen
US20060287263A1 (en) 2004-07-18 2006-12-21 Csl Limited Methods and compositions for inducing antigen-specific immune responses
EP1776105A2 (en) 2004-07-18 2007-04-25 Coley Pharmaceutical Group, Ltd Methods and compositions for inducing innate immune responses
US7887811B2 (en) * 2005-05-24 2011-02-15 Neovacs Method for preparing a stable immunogenic product comprising antigenic heterocomplexes of TNFα and a carrier protein
CN101594877A (zh) * 2005-11-02 2009-12-02 杜克大学 同时的化学疗法和免疫疗法
JP2010536341A (ja) * 2007-08-15 2010-12-02 アムニクス， インコーポレイテッド 生物学的に活性なポリペプチドの特性を改変するための組成物および方法
SG187410A1 (en) * 2007-12-28 2013-02-28 Baxter Int Recombinant vwf formulations

Similar Documents

Publication Publication Date Title
JP7853711B2 (ja) チューブリシン類縁体と細胞結合分子との共役体の製剤
JP2013531679A5 (https=)
IL325353A (en) Incretin analogs and their use
KR20220024914A (ko) 분지형 링커를 사용한 세포독성제 대 세포 결합 분자의 접합체
CN111971062A (zh) 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途
JP2021512881A5 (https=)
JP2016534052A5 (https=)
RU2011127913A (ru) Составы, содержащие антитела
KR20200097295A (ko) 분지형 링커를 갖는 튜불리신 유사체의 접합체
JP2011173914A5 (https=)
JP2021504372A5 (https=)
JP2013515049A5 (https=)
KR20210122319A (ko) 비스-링키지를 사용한 세포독성 약물의 접합
KR20090021298A (ko) 항-ｅｇｆｒ 항체의 동결건조 제제
WO2016154621A1 (en) SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
IL294463A (en) Methods for treating or preventing eye conditions
JP2013511557A5 (https=)
JP2017514868A5 (https=)
RU2013128361A (ru) Her2-связывающие белки, меченые комплексом 18f-фторида алюминия и nota
JP2024508762A5 (https=)
RU2020109881A (ru) Агонисты рецепторов glp-1/глюкагона в лечении жировой болезни печени и стеатогепатита
CN111148510A (zh) 用于治疗性蛋白质的冻干药物配制品的方法
JP2024506940A5 (https=)
JP2007534698A5 (https=)
JP7126270B2 (ja) Ｎｐｒａアゴニスト、組成物およびその使用